课题基金 / 基金详情

Host and microbial risk factors of oral thrush in cancer patients receiving chemotherapy

Host and microbial risk factors of oral thrush in cancer patients receiving chemotherapy
接受化疗的癌症患者鹅口疮的宿主和微生物危险因素
批准号:
10677005
负责人:
Patricia Diaz
金额:
$77.08万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-04 至 2027-05-31
关键词:
AdhesionsAffectAnimal ModelAntifungal AgentsAreaBacteriaBioinformaticsCancer CenterCancer PatientCandida albicansCharacteristicsChemotherapy-Oncologic ProcedureClinicalClinical ResearchCoculture TechniquesDataDefectDental Plaque IndexDevelopmentDoseEpitheliumEtiologyFilamentFunctional disorderFutureGene ExpressionGenetic TranscriptionGoalsHabitsHumanImmuneImmunologicsIn VitroIncidenceIndividualInfectionInfusion proceduresIntakeInvadedKnowledgeLactobacillusLeadLesionLeukopeniaMeasuresMediatingMedicalMedical HistoryMendelian disorderModelingMucous MembraneMulti-Drug ResistanceNeutropeniaNutritionalObservational StudyOralOral candidiasisOral mucous membrane structurePathogenicityPatient SchedulesPatientsPeripheralPilot ProjectsPlayPopulationPorphyromonasPredisposing FactorPredispositionPreventionPrevention strategyPreventivePrevotellaPropertyQuality of lifeROC CurveResearch InfrastructureResistant candidaRiskRisk FactorsRisk MarkerRoleSalivarySamplingSeveritiesSmokingStreptococcusSystemic infectionTestingTherapeutic InterventionTimeVirulenceVirulence FactorsXerostomiabacteriomecancer therapychemotherapyclinical applicationclinically relevantcohortcomorbiditydesignexperimental studyfuture implementationin vivolongitudinal analysismachine learning modelmicrobialmicrobiomemicrobiome compositionmouse modelmycobiomeneutrophiloral bacteriaoral microbiomeoral mucositisoropharyngeal thrushpatient populationpredictive modelingpreventive interventionprospectiveresponsetherapy developmenttool

项目摘要

项目成果

Patricia Diaz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SUMMARY The factors that underline susceptibility to oropharyngeal candidiasis (OPC; thrush) caused by Candida albicans in different populations are not well understood. In individuals with specific monogenic disorders, OPC susceptibility is dictated by defects in mucosal immune defenses and/or epithelial barrier function. In cancer patients undergoing chemotherapy, OPC has been attributed to the severity of leukopenia, but there is incomplete understanding of the role other predisposing factors play in this setting. Mouse models have shown that oral bacteria contribute to the severity of chemotherapy-associated OPC by promoting C. albicans filamentation and epithelial damage. There is a need, however, to obtain evidence from human studies on factors that predispose patients receiving chemotherapy to OPC, including an understanding of the role played by bacteria, and a delineation of the host antifungal defenses that when compromised by chemotherapy lead to OPC. The study of OPC susceptibility in chemotherapy is facilitated by the opportunity to evaluate individuals prior to and during progression of OPC. This proposal is based on preliminary data obtained in a recent pilot study using this unique clinical model in which we established that host clinical characteristics and the oral microbiome composition assessed prior to chemotherapy constitute risk factors for OPC. We also evaluated the manner in which chemotherapy predisposes to OPC, discovering hyposalivation and neutropenia as important contributors. These results suggest a multi-factorial etiology for OPC during chemotherapy. The goal of this proposal is to determine the factors that underline susceptibility to OPC in chemotherapy recipients. Through clinical and in vitro mechanistic studies, this proposal will test the hypothesis that specific clinical, immunological and microbial characteristics dictate susceptibility to OPC during chemotherapy. To gain a better understanding of the pathophysiology of OPC during chemotherapy three specific aims are proposed. In Aim 1 we will develop a machine-learning model based on baseline medical and oral characteristics and the oral microbiome to predict OPC incidence in chemotherapy recipients. We anticipate creating a tool to identify, pre-infusion, individuals susceptible to OPC. In Aim 2, we will identify, longitudinally, the interactions between chemotherapy, salivary antifungal defenses, mucosal integrity and the oral microbiome that are associated with OPC incidence. We expect these studies will reveal the host and microbiome factors that when affected by chemotherapy predispose to OPC. In Aim 3, we will evaluate through in vitro studies the potential for bacterial species associated with OPC lesions to modify the virulence of C. albicans. These studies will identify critical bacterial partners of C. albicans and elucidate the manner in which inter-kingdom interactions may contribute to chemotherapy-associated OPC. Altogether, these studies will provide clinically-relevant evidence on the etiology of OPC during chemotherapy that we expect will contribute to guide the development of preventive and therapeutic interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Host and microbial risk factors of oral thrush in cancer patients receiving chemotherapy
Mechanisms of Cell Death and Inflammation in Chemotherapy-Induced Oral Mucositis
In vitro models of subgingival communities and their in vivo pathogenic potential
In vitro models of subgingival communities and their in vivo pathogenic potential
海外基金